Netflixs Duffer Brothers Series The Boroughs Faces Mixed Reception Content Strategy Under Scrutiny Geopolitical Risk Remains Elevated as Iran Defies US Pressure Strait of Hormuz Uncertainty Persists Apollo Micro Systems Shares Surge 13 After Strong Q4 Results Technicals Suggest Continued Momentum Republican Hardliners Warn Trump Conceding Too Much in Iran Nuclear Talks House Hacking Strategy How One Couple Mortgaged 9 Properties in Under a Decade BOJs Rate Hike Dilemma Could Tightening Actually Push LongTerm Yields Higher BG Q1 2026 Earnings Earnings Surge 103 Above Estimates as Agribusiness Strength Outpaces Expectations Digi International Inc DGII Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction Youdao Inc Q1 2026 Earnings EPS Misses Estimates but Stock Surges on Broader Sentiment Energizer Holdings Q1 2026 Earnings EPS Crushes Estimates by Over 100 as Cost Initiatives Drive Profitability Perspective Therapeutics Inc CATX Q1 2026 Earnings Loss Narrows Sharply Stock Gains 284 UTSI Q4 2019 Earnings EPS Misses Estimates by Wide Margin Tandem Diabetes Care TNDM Slips 24 as Support Levels Come Into Focus Graham Holdings GHC Edges Higher as Shares Test Key Resistance Near 1160 FutureFuel Corp FF Edges Higher Amid Modest Trading Activity Sunrun RUN Holds Steady Near 1450 as Solar Sector Consolidates BBVA Surges 393 Breaking Through Resistance Levels US Official Alleges Japans Role in Fentanyl Smuggling Raising Trade and Compliance Concerns SNAL Q1 2026 Earnings EPS Surges Past Estimates Amid Tight Cost Controls Trinity Industries Stock Slides 117 as Price Approaches Key Support Level AAUC Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response AVX Q1 2026 Earnings Loss Per Share and Stock Decline Highlight Challenges ULCC Q1 2026 Earnings Narrowerthanexpected loss as cost discipline aids results CVU Q1 2021 Earnings EPS Surges Past Estimates Stock Gains JUNS Q4 2025 Earnings NarrowerThanExpected Loss Reflects Cost Control Efforts Despite No Revenue PPBT Q1 2025 Earnings Biotech Reports Net Loss Amid Ongoing Clinical Development CRISPR Therapeutics Q1 2026 Earnings Slight EPS Miss as Clinical Pipeline Progresses